J&J case: Government asks ‘victims’ to approach central or state panel

NEW DELHI: The government Tuesday issued a public notice stating that patients suffering from disability due to faulty articular surface replacement (ASR) hip implants can approach either the central expert committee or the state-level panel.

In case the affected patients intend to approach the central expert committee, they may write to the legal cell of the Central Drugs Standard Control Organisation, FDA Bhavan on Kotla Road, New Delhi.

They may send an email on legalcell@cdsco.nic.in.

If the affected patients approach the state-level committee, they may write to the concerned state drug controller who will be the member secretary of the state-level committee.

The Centre, earlier this month, constituted the central expert committee under the chairmanship of R K Arya, director of Sports Injury Centre at Safdarjung Hospital, to determine the quantum of compensation to be given to patients who have faulty hip implants, manufactured by DePuy International, a subsidiary of Johnson & Johnson.

Apart from the five-member expert panel, the Union Health Ministry has asked principle/health secretaries of all the states and the Union Territories to constitute separate committees so that they can receive such complaints from the affected patients.

The move came after a panel, constituted earlier by the Union Health Ministry to investigate complaints about articular surface replacement (ASR) hip implant devices, said in its report that the pharma giant “suppressed” facts on the harm of surgeries afterwards, which was conducted on patients in India using “faulty” hip replacement systems.

It had also suggested that the company pay compensation of around Rs 20 lakh to the affected patients. Some of the patients who had suffered due to the faulty implants had questioned the panel’s recommendation of the paltry amount, saying it was like “rubbing salt into their wounds”.

The Health Ministry, in its order dated August 30, has asked the central expert committee to submit its recommendation to the Central Drugs Standard Control Organisation (CDSCO) within 45 days of receiving recommendations from the state-level panels.

The order had said a committee under the chairmanship of Arun Kumar Aggarwal has given its report which has been accepted by the central government with certain modifications.

“Now the central government has decided to constitute a central expert committee to determine the quantum of compensation, as admissible under the law, in respect of faulty ASR hip implants manufactured by M/s DePuy International Limited, UK and implanted in India,” the had order said.

  • Related Posts

    Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

    AiMeD welcomes the move long overdue to boost India’s Regulatory Framework New Delhi: 21 Drug Inspectors have been promoted to Assistant Drugs Controllers (India) under CDSCO. It was long unmet…

    Yashoda Medicity lifts Benchmark in Critical Care to New High

    With the introduction of North India’s first Advanced VitalGo Total Lift Bed Technology Ghaziabad/ New Delhi: In an ideal hospital, critical care is most paramount and it is also the…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad

    Mumbai Crime Branch cracks down on 5 alleged fake doctors, one found to be only Class 12 pass

    Mumbai Crime Branch cracks down on 5 alleged fake doctors, one found to be only Class 12 pass

    DCA raids med shops for violations over sale of weight-loss drugs

    DCA raids med shops for violations over sale of weight-loss drugs

    CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

    CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

    Lilly takes 6 companies to court for selling retatrutide knockoffs

    Lilly takes 6 companies to court for selling retatrutide knockoffs

    FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

    FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked